A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy

Despite advances in ovarian cancer (OC) therapy, recurrent OC remains a poor-prognosis disease. Because of the close interaction between OC cells and the tumor microenvironment (TME), it is important to develop strategies that target tumor cells and engage components of the TME. A major obstacle in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordoloi, Devivasha, Bhojnagarwala, Pratik S., Perales-Puchalt, Alfredo, Kulkarni, Abhijeet J., Zhu, Xizhou, Liaw, Kevin, O’Connell, Ryan P., Park, Daniel H., Kulp, Daniel W., Zhang, Rugang, Weiner, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746812/
https://www.ncbi.nlm.nih.gov/pubmed/36509287
http://dx.doi.org/10.1172/jci.insight.162553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746812/
https://www.ncbi.nlm.nih.gov/pubmed/36509287
http://dx.doi.org/10.1172/jci.insight.162553

Ejemplares similares